Provided by Tiger Trade Technology Pte. Ltd.

Alexander's

255.07
-0.6400-0.25%
Post-market: 255.070.00000.00%16:10 EST
Volume:96.39K
Turnover:24.68M
Market Cap:1.30B
PE:35.73
High:259.23
Open:257.79
Low:250.17
Close:255.71
52wk High:260.84
52wk Low:189.05
Shares:5.11M
Float Shares:2.13M
Volume Ratio:0.97
T/O Rate:4.53%
Dividend:18.00
Dividend Rate:7.06%
EPS(TTM):7.14
EPS(LYR):8.46
ROE:22.99%
ROA:3.28%
PB:10.15
PE(LYR):30.13

Loading ...

Earning Preview: Alexander's Q4 revenue is expected to decrease by 3.26%, and institutional views are limited and cautious

Earnings Agent
·
Feb 02

ALX Oncology Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 05

Alexander's Keeps Quarterly Dividend at $4.50 a Share, Payable Feb. 27 to Shareholders of Record on Feb. 17

MT Newswires Live
·
Feb 05

Alexander's Inc. zahlt Quartalsdividende von 4,50 US-Dollar je Aktie

Reuters
·
Feb 05

Alexander's Inc. Declares $4.50 Quarterly Dividend

Reuters
·
Feb 05

What Atlas Arteria (ASX:ALX)'s Q4 Toll Revenue Growth Means For Shareholders

Simply Wall St.
·
Feb 02

ALX Oncology announces major underwritten public equity offering

TIPRANKS
·
Jan 30

ALX Oncology Announces Pricing of Underwritten Offering

GlobeNewswire
·
Jan 30

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

GlobeNewswire
·
Jan 30

ALX Oncology Expands Inducement Equity Plan for Hiring

TIPRANKS
·
Jan 22

Alexander's Inc. Publishes Update to Financial Calendar

Reuters
·
Jan 21

ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial

TIPRANKS
·
Jan 08

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

GlobeNewswire
·
Jan 08

Alexander’s Completes Restructuring of Retail Loan at 731 Lexington Avenue

GlobeNewswire
·
Dec 29, 2025

Alexander’s (ALX) Valuation After Rego Park II Refinancing and New $175 Million Interest-Only Loan

Simply Wall St.
·
Dec 11, 2025

Alexander’s Completes $175 Million Refinancing of Rego Park Ii

THOMSON REUTERS
·
Dec 09, 2025

Alexander's Inc. Secures $175 Million Refinancing for Rego Park II Shopping Center

Reuters
·
Dec 09, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

GlobeNewswire
·
Dec 07, 2025

Henderson Land Development Files Directors List to HKEX

Reuters
·
Dec 01, 2025

PT International Development Corporation Files Directors List to HKEX

Reuters
·
Nov 30, 2025